Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
60 results about "Endotoxic shock" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Endotoxic shock. Septic shock due to release of endotoxins by gram-negative bacteria. Endotoxins are lipopolysaccharides in the cell walls that are released during both reproduction and destruction of the bacteria.
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
InactiveUS20050125044A1Inhibition releaseImplantable neurostimulatorsHeterocyclic compound active ingredientsEfferentEndotoxic shock
A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
InactiveUS20090248097A1Implantable neurostimulatorsHeterocyclic compound active ingredientsEfferentEndotoxic shock
A method of inhibiting the release of a proinflammatory cytokine in a cell is disclosed. The method comprises treating the cell with a cholinergic agonist. The method is useful in patients at risk for, or suffering from, a condition mediated by an inflammatory cytokine cascade, for example endotoxic shock. The cholinergic agonist treatment can be effected by stimulation of an efferent vagus nerve fiber, or the entire vagus nerve.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
High affinity antibodies against HMGB1 and methods of use thereof
InactiveUS20060099207A1Reduce bone loss and/or cartilage damageAntibacterial agentsAntibody mimetics/scaffoldsReperfusion injuryAllograft rejection
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:MEDIMMUNE LLC
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
InactiveUS8914114B2Implantable neurostimulatorsHeterocyclic compound active ingredientsSacral nerve stimulationEfferent
Owner:THE FEINSTEIN INST FOR MEDICAL RES
High affinity antibodies against HMGB1 and methods of use thereof
InactiveUS7585504B2Reduce bone loss and/or cartilage damageAntibacterial agentsAntibody mimetics/scaffoldsReperfusion injuryAllograft rejection
Owner:MEDIMMUNE LLC
Method for treating the endotoxic shock in mammals
InactiveUS6429188B1Inhibit productionImprovement in evolutionBiocidePeptide/protein ingredientsToxinInterleukin 6
Method for the treatment of endotoxic shock in mammals. The use of vasoactive intestinal peptide (VIP) and peptide activating hypofissiary adenylate cyclase (PACAP) is described in the treatment of endotoxic shock in mammals. These substances inhibit the production of tumor necrosis factor (TNF) and interleukin 6 (IL-6).
Owner:UNIV COMPLUTENSE DE MADRID
Cell permeable peptides for inhibition of inflammatory reactions and methods of use
The present invention relates to the delivery of biologically active molecules, such as peptides, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent signal peptide. Such delivery can be utilized, for example, to treat and / or prevent inflammatory conditions, e.g., but not limited to, systemic inflammatory reactions such as endotoxic shock, localized inflammatory reactions such as inflammatory skin diseases and conditions, and inflammatory diseases such as autoimmune diseases.
Owner:VANDERBILT UNIV
Inhibition of Inflammatory Cytokine Production With Tanshinones
InactiveUS20090221542A1Reduce and prevent physiologic effectReduce and prevent effectAntibacterial agentsBiocideEndotoxic shockNo production
Provided are methods of attenuating release of a proinflammatory cytokine from a mammalian cell. Also provided are methods of inhibiting or treating an inflammatory cytokine cascade in a mammal. Further provided are methods of treating a mammal at risk for or undergoing sepsis, septicemia, and / or endotoxic shock. Additionally provided are methods of attenuating NO release from a mammalian cell. Also provided are methods of attenuating NO production in a mammal at risk for, or having, a disorder mediated by excessive NO production.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Substituted imides
Novel imides are inhibitors of tumor necrosis factor alpha and can be used to combat cachexia, endotoxic shock, and retrovirus replication. A typical embodiment is (R)-2-Phthalimido-3-(3′,4′-dimethoxyphenyl)propane.
Owner:CELGENE CORP
High Affinity Antibodies Against HMGB1 and Methods Of Use Thereof
InactiveUS20100061987A1Reduce bone loss and/or cartilage damageAntibacterial agentsAntipyreticAntiendomysial antibodiesAllograft rejection
Owner:MEDIMMUNE LLC
High affinity antibodies against hmgb1 and methods of use thereof
InactiveUS20090169546A1Useful in treatmentReduce hyperostosisAntipyreticMicrobiological testing/measurementReperfusion injurySpinal cord
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn s disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:CORNERSTONE THERAPEUTICS +1
Matrix metalloproteinase-9 polypeptide inhibitor 4 and its application
ActiveCN102268069AImprove survival rateAvoid damagePeptide/protein ingredientsAntipyreticFactor iiWilms' tumor
The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-(D-Pyr)-(D-Cys)-Bip-Arg-Gly-Glu which is a brand new sequence (D-Pyr is D-type pyridine alanine, D-Cys isD-type cysteine, and Bip is diphenyl alanine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.
Owner:CHINA PHARM UNIV
Matrix metalloproteinase-2 polypeptide inhibitor and application
ActiveCN103304634AImprove survival rateAvoid damagePeptide/protein ingredientsAntipyreticCancer researchAcute inflammatory reaction
The invention relates to the field of drugs and in particular relates to polypeptides capable of inhibiting matrix metalloproteinase-2 and tumor necrosis factor liberase and also capable of relieving damage of acute inflammatory reaction to an organism. The sequence of the polypeptides is Trp-Ser-Asn-Val-Gly-Gly-Gly-Gly-Glu-Lys-Met, which is a brand new sequence; the polypeptides are capable of inhibiting the activities of matrix metalloproteinase-2 and the tumor necrosis factor liberase in vitro on the level of 1 micromole, and also capable of increasing the survival rate of endotoxic shock mice in in vivo tests; the polypeptides have potential new drug development value.
Owner:GUANGZHOU FOREVERGEN BIOTECH CO LTD
Application of parthenolide as platelet-activating factor (PAF) antagonist
InactiveCN102579426AReduce contentAntibacterial agentsOrganic active ingredientsThrombusHepatic fibrosis
The invention discloses application of parthenolide as a platelet-activating factor (PAF) inhibitor. The parthenolide can be used as a safe PAF antagonist to be applied to treatment, auxiliary treatment and prevention of diseases such as thrombus, atherosclerosis, ischemic cardio-vascular disease, cerebral ischemia, acute pancreatitis, endotoxic shock, asthma, hepatic fibrosis and hepatocirrhosis, injury of nerve, gastrointestinal ulcer and necrosis, psoriasis, systemic lupus erythematosus and acquired immune deficiency syndrome related to platelet-activating factor.
Owner:韩颖
Matrix metalloproteinase-9 polypeptide inhibitor 1 and its application
InactiveCN102268068AImprove survival rateAvoid damagePeptide/protein ingredientsAntipyreticArginineFactor ii
The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting substrate metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction to an organism. The sequence of the polypeptide is Pro-Arg-Cys-(D-Bip)-(D-Arg)-Gly-Glu which is a brand new sequence (D-Bip is D-type diphenyl alanine, and D-Arg is D-type arginine). The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate of an endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.
Owner:CHINA PHARM UNIV
Compositions for importing biologically active molecules into cells
The present invention relates to the delivery of biologically active molecules, such as peptides, nucleic acids and therapeutic agents, into the interior of cells by administering to the cells a complex comprising the molecule linked to an importation competent signal peptide. Such delivery can be utilized for purposes such as peptide therapy, gene transfer, and antisense therapy to regulate and / or eradicate systemic inflammatory response syndromes such as endotoxic shock.
Owner:VANDERBILT UNIV
Immunotherapeutic agents
Cyano and carboxy derivatives of substituted styrenes are inhibitors of tumor necrosis factor α, nuclear factor κB, and phosphodiesterase and can be used to combat cachexia, endotoxic shock, retrovirus replication, asthma, and inflammatory conditions. A typical embodiment is 3,3-bis-(3,4-dimethoxyphenyl)acrylonitrile.
Owner:CELGENE CORP
High Affinity Antibodies Against HMGB1 and Methods of Use Thereof
InactiveUS20110287023A1Reduce bone lossReduce cartilage damageMetabolism disorderAntipyreticReperfusion injuryFactor ii
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:MEDIMMUNE LLC +1
Compounds, Compositions and Methods for the Treatment of Inflammatory Diseases
InactiveUS20120058998A1Avoid cell deathBiocideNervous disorderInsulin dependent diabetesUlcerative colitis
A method of inhibiting the inflammatory process, the method comprising administering to a mammal suffering from inflammation a therapeutically effective amount of a pharmaceutical composition comprising a compoundwhere:R is a C1-C10 alkylene group, in which, when the number of carbon atoms is at least 2, there are optionally 1 or 2 non-adjacent double bonds; 1 to 3 non-adjacent methylene groups are optionally replaced by NR1 (where R1 is H, alkyl, or acyl), O, or S; and 1 or 2 methylene groups are optionally replaced by a carbonyl or hydroxymethylene group and pharmaceutically acceptable esters or salts of the compounds and wherein the inflammatory process results from a disease selected from the group consisting of ulcerative colitis, endotoxic shock, rheumatoid arthritis, juvenile arthritis, osteoarthritis, psoriasis, Crohn's disease, inflammatory bowel disease, multiple sclerosis, insulin dependent diabetes mellitus, gout, psoriatic arthritis, reactive arthritis, vital or post-viral arthritis and ankylosing spondylarthritis.
Owner:PROTAMED
Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
ActiveUS20110190303A1BiocideSenses disorderRESPIRATORY DISTRESS SYNDROME ADULTObstructive chronic bronchitis
The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjuctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
Owner:GLENMARK PHARMA SA
Treatment of inflammation and/or endotoxic shock
This invention provides the use of one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for treatment of inflammation and / or endotoxic shock and / or treatment of wounds and / or reduction of levels of inflammatory chemokines in a subject, and one or more peptides derived from the C-terminal end of a Chemerin protein, or analogs or derivatives thereof for use in the treatment of inflammation and / or endotoxic shock, and / or wounds, or for the reduction of levels of inflammatory mediators.
Owner:OXFORD UNIV INNOVATION LTD
High affinity antibodies against HMGB1 and methods of use thereof
InactiveUS8129130B2Useful in treatmentReduce hyperostosisAntipyreticMetabolism disorderReperfusion injuryAllograft rejection
Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present invention and pharmaceutical compositions comprising the same are useful for many purposes, for example, as therapeutics against a wide range of inflammatory diseases and disorders such as sepsis, rheumatoid arthritis, peritonitis, Crohn's disease, reperfusion injury, septicemia, endotoxic shock, cystic fibrosis, endocarditis, psoriasis, psoriatic arthritis, arthritis, anaphylactic shock, organ ischemia, reperfusion injury, and allograft rejection. In addition, the high affinity antibodies of the present inventions are useful as diagnostic antibodies.
Owner:MEDIMMUNE LLC +1
Oxime Derivatives as Inhibitors of Macrophage Migration Inhibitory Factor
Provided are compounds of formula (I) and other compounds. Also provided are pharmaceutical compositions comprising these compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal, and methods of treating a mammal having sepsis, septicemia, and / or endotoxic shock.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Phenolic Hydrazone Macrophage Migration Inhibitory Factor Inhibitors
InactiveUS20090170951A1Inhibit migrationInhibitory activityBiocideSenses disorderAbnormal tissue growthAutoimmune condition
Provided are various compounds of Formula (I): Also provided are pharmaceutical compositions comprising the above compounds. Additionally, methods of inhibiting macrophage migration inhibitory factor (MIF) activity in a mammal are provided, as are methods of treating or preventing inflammation in a mammal. Further provided are methods of treating a mammal having sepsis, septicemia, and / or endotoxic shock. Also provided are methods of treating a mammal having an autoimmune disease, and methods of treating a mammal having a tumor.
Owner:THE FEINSTEIN INST FOR MEDICAL RES
Anti-inflammation effect and application of immuno-regulatory molecule Rhbdd3
InactiveCN105079796ARegulation levelImprove survival rateAntibacterial agentsAntimycoticsInflammatory factorsDendritic cell
The invention relates to anti-inflammation effect and application of an immuno-regulatory molecule Rhbdd3, in particular to protein 3 (namely Rhbdd3) or Rhbdd3 coding sequence having an rhomboid structure domain and application of promoter or inhibitor in preparation of drug used for regulating and controlling dendritic cell activation and / or inflammatory factor level or a reagent box, and further relates to application and an application method of the above substance in resisting infection and treating chronic inflammatory diseases caused by infection and corresponding drug, drug combination or reagent box. The immuno-regulator molecule can be used for inhibiting activation of infected dendritic cells and excessive generation of inflammatory factors, increasing survival rate and survival time of organisms in endotoxic shock and protecting visceral organs like lung after being infected from inflammatory damage or can be used for immunoregulation, and has wide application prospect.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Matrix metalloproteinase-9 polypeptide inhibitor 2 and its application
InactiveCN102268070AImprove survival rateAvoid damagePeptide/protein ingredientsAntipyreticSaxitoxinOrganism
The invention relates to the field of medicaments, in particular to a polypeptide which has the effects of inhibiting metal prolease-9 and tumor necrosis factor liberase and relieving the damage of an acute inflammatory reaction on an organism. The sequence of the polypeptide is Pro-Arg-(D-Cys)-Bip-Arg-Gly-Glu (Bip is D-type diphenyl alanine, D-Cys is D-type cysteine), which is a brand new sequence. The polypeptide can be used for inhibiting the activities of the substrate metal prolease-9 and the tumor necrosis factor liberase on 1 micromole level in vitro and increasing the survival rate ofan endotoxic shock mouse in an in-vivo test, and has a potential new medicament development value.
Owner:CHINA PHARM UNIV
Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors
The present invention relates to novel Phosphodiesterase type 4 (PDE4) inhibitors of the formula (1) and analogs, tautomers, enantiomers, diasteromers, regioisomers, stereoisomers, polymorphs, pharmaceutically acceptable salts, appropriate N-oxides, pharmaceutically acceptable solvates thereof and the pharmaceutical compositions containing them which are useful in the treatment of allergic and inflammatory diseases including asthma, chronic bronchitis, atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, reperfusion injury of the myocardium and reperfusion injury of the brain, chronic glomerulonephritis, endotoxic shock and adult respiratory distress syndrome.
![Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors](https://images-eureka.patsnap.com/patent_img/86f476e1-5787-43e1-ab06-b0cf1c0bc9ec/US07943634-20110517-C00001.png "Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors")
![Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors](https://images-eureka.patsnap.com/patent_img/86f476e1-5787-43e1-ab06-b0cf1c0bc9ec/US07943634-20110517-C00002.png "Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors")
![Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors](https://images-eureka.patsnap.com/patent_img/86f476e1-5787-43e1-ab06-b0cf1c0bc9ec/US07943634-20110517-C00003.png "Substituted benzo[4,5]furo[3,2-c]pyridine derivatives as PDE 4 inhibitors")
Owner:GLENMARK PHARMA SA
Anti-inflammatory effect of novel anti-inflammatory molecular DRP, implementation method and application
InactiveCN101897951AProtect liver functionImprove survival rateAntibacterial agentsPeptide/protein ingredientsInflammatory factorsFactor ii
The invention relates to anti-inflammatory effect of novel anti-inflammatory molecular DRP, an implementation method and application, in particular to application of death resistant protein (DRP) in resisting bacterial infection and an application method. The invention provides the application method of the molecule in resisting bacterial infection and a corresponding immunological principle. The invention discloses application and strategy of the molecule in resisting the bacterial infection, particularly in preventing and treating infectious shock and endotoxic shock caused by the bacterial infection. The invention proves that the molecule can inhibit the generation of inflammatory factors after the bacterial infection, improve the survival rate of bodies in the endotoxic shock and protect the infected organs such as liver and the like from inflammation injury.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Compound of single sugar cluster and heterozygous sugar cluster, preparation method and applications thereof
The invention discloses a compound of a single sugar cluster and a heterozygous sugar cluster, which are shown in formula (I), wherein the definition of a substituent group in the compound of the formula (I) is disclosed in detail in the specification. In addition, the invention also discloses a preparation method and a pharmaceutical composition of the compound. The compound has adhesion resistance and a protecting function on endotoxic shock.
Owner:PEKING UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com